Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123913 · ClinicalTrials.gov registry record · Phase 1
Study of Testosterone and rHGH in FSHD
A Phase 1 study, sponsored by University of Rochester.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03123913 is a Phase 1 study that has completed, run by University of Rochester. The registered enrollment target is 20 participants.
The verdict
NCT03123913, a Phase 1 study, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.
Interventions
- DRUG Somatropin
- DRUG Testosterone Enanthate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-18 |
| Est. Completion | 2022-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123913
The ClinicalTrials.gov registry entry for NCT03123913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Somatropin is the first listed.
NCT03123913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123913 about?
NCT03123913 is a clinical study titled "Study of Testosterone and rHGH in FSHD". The purpose of this study is to investigate the safety and tolerability of combination therapy with recombinant human growth hormone (rHGH) and testosterone in adult male patients with facioscapulohumeral muscular dystrophy (FSHD) over 24 weeks.
What is the current status of trial NCT03123913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-18. Estimated completion is 2022-03-28.
What interventions are being tested in trial NCT03123913?
The interventions under investigation include: Somatropin (DRUG), Testosterone Enanthate (DRUG).
Who is sponsoring clinical trial NCT03123913?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.